By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...

Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and ...

(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...

The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, ...